Intrahepatic cholangiocarcinoma, often abbreviated ICC, arises from the epithelial cells lining the small bile ducts within the liver. It is notoriously difficult to detect early, and most patients are diagnosed at an advanced stage when surgical resection is no longer possible. Even with modern imaging and multidisciplinary treatment, prognosis remains poor. Clinicians have increasingly turned to molecular testing to identify actionable pathways, but the landscape of RNA-based regulators in this cancer is still incompletely understood. The new study adds a critical piece to that puzzle by connecting an epitranscriptomic modifier to a circular RNA and tracing the consequences all the way to tumor growth in living animals.

ALKBH5 is an m6A demethylase, meaning it removes N6-methyladenosine marks from RNA molecules. These marks are among the most common chemical modifications found on messenger RNAs and noncoding RNAs in mammalian cells, and they influence RNA stability, translation, and export from the nucleus. By stripping these marks, ALKBH5 can alter the fate of specific transcripts. Prior research had already implicated ALKBH5 in ICC, showing that it sustains the expression of BUB1B and supports cell proliferation, and that it regulates PD-L1 expression and shapes the tumor immune environment. The current investigation extends that story by asking which circular RNAs ALKBH5 controls in this cancer.

Circular RNAs, or circRNAs, are covalently closed RNA molecules formed when a downstream splice donor joins an upstream splice acceptor, producing a ring instead of a linear chain. Because they lack free ends, circRNAs are resistant to exonuclease degradation and can persist in cells far longer than their linear counterparts. Many circRNAs act as competing endogenous RNAs, or ceRNAs, meaning they soak up microRNAs that would otherwise repress target messenger RNAs. This sponging mechanism creates a regulatory layer in which a noncoding RNA can indirectly increase the expression of a protein-coding gene by titrating away its repressive microRNA.

To identify the key circRNA downstream of ALKBH5, the researchers collected sixteen clinical samples of ICC tumor tissue and matched paracancerous tissue. They confirmed that ALKBH5 was significantly overexpressed in the tumors compared with the adjacent noncancerous tissue. They then performed circRNA sequencing to profile the circular transcriptome and used bioinformatic prediction tools to identify candidate microRNAs and downstream messenger RNAs connected to the top hit. That hit was circ_0032649, a circular RNA whose abundance tracked with ALKBH5 expression in the clinical samples.

The team then depleted ALKBH5 in ICC cell lines using in vitro transfection and measured the consequences with a battery of functional assays. Cell counting kit-8 assays revealed a significant drop in cell viability. Colony formation assays showed reduced clonogenic capacity. Flow cytometry demonstrated that ALKBH5 depletion induced G1-phase cell cycle arrest, meaning cells accumulated before DNA synthesis rather than progressing into the S phase. The depletion also weakened apoptosis resistance, meaning the cancer cells became more willing to undergo programmed cell death, and it suppressed epithelial-mesenchymal transition, the process by which epithelial cancer cells acquire invasive, motile characteristics. Together, these results established ALKBH5 as a central supporter of ICC cell fitness.

Mechanistically, the researchers used RNA immunoprecipitation to show that ALKBH5 physically binds circ_0032649. They then used dual-luciferase reporter assays to demonstrate that circ_0032649 acts as a sponge for miR-4755-3p, a microRNA that would otherwise repress ORAI2 messenger RNA. When circ_0032649 is abundant, it titrates away miR-4755-3p, allowing ORAI2 expression to rise. ORAI2 is a subunit of store-operated calcium entry channels, which are plasma membrane calcium channels that refill intracellular calcium stores after depletion. Prior work in gastric cancer had shown that ORAI2 promotes tumorigenicity and metastasis through PI3K/Akt signaling and MAPK-dependent focal adhesion disassembly, and studies in breast cancer cells have linked ORAI2 to cell cycle progression. The new findings place ORAI2 at the downstream end of an ALKBH5-circ_0032649-miR-4755-3p ceRNA axis in ICC.

To test whether this axis matters in living organisms, the researchers established a xenograft tumor model by implanting ICC cells into immunocompromised mice. They then delivered lentivirus intratumorally to manipulate ALKBH5 and circ_0032649 expression within the growing tumors. The results showed that the ALKBH5/circ_0032649 axis promoted ICC tumor progression in vivo and altered the expression of the ceRNA regulatory axis, confirming that the molecular chain identified in cell culture also operates within a living tumor microenvironment. The animal experiments were approved by an institutional animal care committee and performed in accordance with ARRIVE guidelines.

The study’s significance lies in connecting an epitranscriptomic modifier to a circular RNA sponge and a calcium channel gene in a single regulatory chain. Prior circRNA research in ICC had identified individual circRNAs such as circSLCO1B3, circACTN4, circUGP2, and circ_0057105 as players in tumor progression, and ALKBH5 had been shown to sustain stemness and regulate immune evasion. But the current work is among the first to show that ALKBH5 directly binds a specific circRNA and uses it to upregulate a calcium channel through microRNA sponging. This adds a mechanistic dimension that links RNA modification chemistry to ion channel biology and tumor growth.

From a translational standpoint, the findings suggest several potential intervention points. Blocking ALKBH5 activity, degrading circ_0032649 with antisense oligonucleotides or small interfering RNAs, or delivering synthetic miR-4755-3p mimics could each disrupt the axis at a different level. Inhibiting ORAI2 or the store-operated calcium entry it mediates represents another possible strategy. Because ALKBH5 is already a subject of drug discovery efforts in other cancers, the new data may accelerate the evaluation of ALKBH5 inhibitors in ICC. The researchers note that their data are available from the corresponding author upon reasonable request, and the work was supported by the National Natural Science Foundation of China and the Natural Science Foundation Project of Guangxi. While clinical application remains distant, the study provides a detailed molecular map that other teams can now use to design targeted experiments and, eventually, therapeutic candidates for this challenging cancer.

Subject of Research: ALKBH5-regulated circ_0032649, acting as a sponge for miR-4755-3p to upregulate ORAI2, facilitates intrahepatic cholangiocarcinoma tumorigenicity

Article Title: ALKBH5-regulated circ_0032649, acting as a sponge for miR-4755-3p to upregulate ORAI2, facilitates intrahepatic cholangiocarcinoma tumorigenicity

Article References: Tang, Y., Zhang, Q., Wen, X., Liu, R., Xie, S., Chen, B., Huang, T., Huang, X., Xie, D., Huang, W., Tang, Z., & Tang, Y. (2026). ALKBH5-regulated circ_0032649, acting as a sponge for miR-4755-3p to upregulate ORAI2, facilitates intrahepatic cholangiocarcinoma tumorigenicity. Molecular Biology Reports, 53(1), Article 1749. https://doi.org/10.1007/s11033-026-12934-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12934-0

Keywords: ALKBH5-regulated, circ, acting, sponge, miR-4755-3p, upregulate, ORAI2, facilitates, intrahepatic, cholangiocarcinoma, tumorigenicity, scientific research

The case, published in Frontiers in Medicine by a team led by Jiankai Long, Jingnan Xue, and Kai Zhou of the People’s Hospital of Anshun City, with collaborators from Peking Union Medical College Hospital, describes an intrahepatic intraductal papillary neoplasm of the bile duct, or IPNB, with low-grade dysplasia of the pancreatobiliary type. IPNB is an uncommon biliary epithelial neoplasm characterized by papillary or villous proliferation within the bile duct lumen, often accompanied by bile duct dilatation and mucin hypersecretion. It is increasingly recognized as an important precursor lesion of cholangiocarcinoma, an aggressive cancer of the bile ducts. The histological grade, invasive status, and subtype of IPNB are closely associated with prognosis and management strategies, which makes accurate preoperative recognition a matter of genuine clinical urgency.

The diagnostic challenge in this case was not simply the rarity of the tumor itself. It was the fact that everything about the patient’s presentation—recurrent biliary symptoms, multiple intrahepatic stones, and evidence of ductal obstruction—could be explained by uncomplicated hepatolithiasis with secondary obstruction. In such settings, the main clinical risk is misinterpreting a true intraductal neoplasm as stone-related biliary disease. The authors emphasize that focal or unilateral bile duct dilatation, localized obstructive change, intraductal soft-tissue components, or abundant mucin may indicate IPNB rather than hepatolithiasis alone, and that recognizing this pitfall is essential for timely intervention.

On admission, physical examination revealed no remarkable findings. Laboratory investigations, including complete blood count, liver and renal function tests, and coagulation profile, were within normal limits. The only abnormality was a mildly elevated serum carbohydrate antigen 19-9, or CA19-9, level of 39.8 U/mL—a tumor marker that can be elevated in biliary malignancies but is nonspecific and can also rise in benign cholestatic conditions. Routine blood work offered no clear signal that a neoplasm was lurking within the left intrahepatic biliary system.

The real clues emerged from cross-sectional imaging. Contrast-enhanced computed tomography demonstrated a focal intraductal adenomatous lesion in the left intrahepatic biliary system with adjacent cystic or aneurysmal dilatation of the affected bile duct, producing the appearance of localized high biliary obstruction. The lesion was centered near the left hepatic hilar region and was associated with unilateral left intrahepatic biliary dilatation. Magnetic resonance imaging and magnetic resonance cholangiopancreatography, or MRCP, further confirmed marked unilateral dilatation of the left intrahepatic bile ducts with focal hilar-level obstructive change and an associated intraductal abnormality. The predominantly unilateral distribution of ductal dilatation and the localized obstructive appearance were atypical for simple hepatolithiasis alone and raised concern for an underlying intraductal biliary neoplasm.

This imaging pattern is technically significant because hepatolithiasis typically produces diffuse, bilateral, or multifocal ductal changes proportional to the stone burden. When dilatation is focal or unilateral and appears disproportionate to the stones, the differential diagnosis should expand beyond stone disease. In this case, the preoperative differential diagnosis included hepatolithiasis with cholangitis, intrahepatic cholangiocarcinoma, mucinous biliary neoplasm, and IPNB. The radiologic-pathologic correlation proved particularly informative: the focal intraductal lesion and adjacent dilated bile duct seen on CT corresponded to the gross finding of papillary adenomatous tissue within a markedly dilated bile duct containing gelatinous material, and to the microscopic finding of papillary epithelial proliferation on histopathology. This correlation helped explain why the lesion was not merely a consequence of stone disease but represented a true intraductal neoplasm.

Given that the lesion appeared localized to the left intrahepatic biliary system and that the patient had recurrent obstructive symptoms, the surgical team selected definitive treatment after comprehensive preoperative evaluation. The patient underwent open left hepatectomy under general anesthesia. Intermittent inflow occlusion using the Pringle maneuver—a technique that temporarily clamps the hepatoduodenal ligament to reduce blood loss during liver resection—was applied, with a total clamping time of 30 minutes. Intraoperative blood loss was approximately 20 mL, and the patient remained hemodynamically stable throughout the procedure. Gross examination of the resected specimen demonstrated a markedly dilated bile duct containing intraductal papillary adenomatous tissue and gelatinous mucinous material. For lesions confined to one intrahepatic biliary system, hepatectomy can provide both definitive diagnosis and curative treatment in a single operation.

Histopathological examination confirmed intrahepatic IPNB with low-grade dysplasia of the pancreatobiliary type. No invasive carcinoma was identified, and all resection margins were negative—findings that carry substantial prognostic weight. Immunohistochemical staining showed that the neoplastic biliary epithelium was positive for CK19, CK7, MUC1, MUC5AC, and MUC6, but negative for MUC2. This mucin profile is technically meaningful because it supports pancreatobiliary differentiation and strengthens subtype classification beyond morphology alone, enabling more meaningful comparison with previously reported cases. The postoperative course was uneventful, and the patient was discharged on postoperative day 10 without documented complications such as bile leakage, hemorrhage, or severe infection.

During two years of outpatient follow-up, the patient remained clinically stable with no evidence of recurrence or major postoperative complications. Her abdominal symptoms resolved after surgery, and her quality of life improved. The latest CT demonstrated postoperative changes after left hepatectomy, possible intrahepatic bile duct calculi or calcifications, mild intrahepatic and extrahepatic bile duct dilatation, and a right renal cyst, but no definite recurrent lesion was reported. After surgery, the patient reported that her pain had resolved and that follow-up examinations were reassuring, expressing satisfaction with the treatment outcome and feeling more secure in her daily life.

The authors caution that even low-grade, completely resected IPNB requires long-term surveillance, because biliary neoplasms may recur or present as multifocal disease. Patients with IPNB should undergo periodic clinical review and hepatobiliary imaging after surgery, especially during the first two postoperative years. The report has limitations: several detailed preoperative radiologic parameters, including reproducible lesion measurements, formal enhancement characteristics, and complete archived MRCP descriptors, were unavailable, and as a single-case report the generalizability of the findings is inherently limited. The two-year follow-up duration may also be insufficient to exclude late recurrence or multifocal disease. Nevertheless, the central message stands: in patients with hepatolithiasis and recurrent biliary symptoms, unilateral or focal intrahepatic duct dilatation, localized obstructive change, and intraductal abnormalities should prompt consideration of IPNB rather than uncomplicated stone disease alone. Early recognition, timely surgical resection for localized disease, and complete pathological evaluation are essential for accurate diagnosis, risk stratification, and follow-up planning—and this case shows how a tumor hiding behind stones can be caught before it becomes cancer.

Subject of Research: Medicine

Article Title: Intrahepatic intraductal papillary neoplasm of the bile duct with low-grade dysplasia presenting as high biliary obstruction and hepatolithiasis: a case report

Article References: Long, J., Xue, J., Xie, N., Zhang, L., & Zhou, K. (2026). Intrahepatic intraductal papillary neoplasm of the bile duct with low-grade dysplasia presenting as high biliary obstruction and hepatolithiasis: a case report. Frontiers in Medicine, 13, Article 1916026. https://doi.org/10.3389/fmed.2026.1916026

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1916026

Keywords: IPNB, bile duct, hepatolithiasis, cholangiocarcinoma, case report, hepatectomy, biliary obstruction, precancerous, mucin, diagnostic pitfall, Intrahepatic, intraductal

The study, known as COMIT-ANZ, was led by researchers at the University of Melbourne’s Austin Health Precinct together with the Prometheus Transplant Collaborative, spanning hospitals from Queensland to Western Australia and Auckland City Hospital in New Zealand. The team set out to measure clinical outcomes for patients who had undergone liver transplantation either knowingly for cholangiocarcinoma or unknowingly, when the tumour was discovered only after the diseased liver had been removed and examined under the microscope. Their findings carry real weight for a subspecialty that is expanding faster than its evidence base.

Cholangiocarcinoma is a malignancy that arises from the epithelial cells lining the bile ducts, the narrow channels that drain bile from the liver into the intestine. It carries a notoriously poor prognosis, and its behaviour depends heavily on where it sits. Intrahepatic cholangiocarcinoma develops within the liver substance itself, while the majority of extrahepatic tumours are perihilar, clustering at the liver hilum where the bile ducts converge. That anatomical distinction is not merely academic; it determines which transplant pathway a patient can access, because the evidence supporting transplantation differs profoundly between the two sites.

For perihilar tumours that cannot be surgically resected, transplantation is only offered when centres have an established neoadjuvant chemoradiotherapy protocol in place, a strategy pioneered at the Mayo Clinic in which patients receive external beam radiotherapy followed by chemotherapy before the transplant itself. International series report five-year overall survival of roughly 53 to 71 percent for these patients. For very early intrahepatic cholangiocarcinoma, defined as a single tumour smaller than two centimetres in a cirrhotic liver, a growing body of retrospective data has convinced the International Liver Transplant Society to endorse transplantation. The catch, as the COMIT-ANZ authors point out, is that nearly all of the data informing that guidance came from North American, Asian and European centres, leaving the applicability to Australia and New Zealand genuinely unknown.

To close that gap, the researchers mined the Australia and New Zealand Liver and Intestinal Transplant Registry, the national registry that has captured transplant activity since the region’s programmes began in 1986. Local transplant unit leads re-identified eligible recipients and entered de-identified clinical data into a REDCap database, capturing demographics, transplant details, explant histology, patient and graft survival, recurrence status and cause of death. The primary outcome was five-year overall survival, with recurrence-free survival as a secondary measure. In total, 64 adult patients were identified who had been transplanted for either known or incidentally detected cholangiocarcinoma or a mixed hepatocellular-cholangiocarcinoma, a rare biphenotypic tumour carrying histological features of both parent cancers.

The demographic profile of these patients was telling. Three-quarters were male, the median age at transplant was 55 years, and the median MELD score, the laboratory measure of liver disease severity used to prioritise waiting-list patients, was 14. Perhaps the most consequential finding was the timing of diagnosis: 75 percent of these tumours were detected incidentally on explant histology, meaning neither the patient nor the surgical team knew the cancer was there before the transplant. Only 16 patients, one quarter of the cohort, were knowingly transplanted for cholangiocarcinoma, and most of those had underlying primary sclerosing cholangitis, an inflammatory condition of the bile ducts that predisposes patients to perihilar tumours.

The survival figures tell a nuanced story. Across all 64 patients, the five-year overall survival was 47 percent, with recurrence-free survival of 60 percent, figures that sit well below the 83 percent five-year survival for liver transplantation in the region overall and the 79 percent for hepatocellular carcinoma. But the all-comer number conceals the real signal. When the researchers stratified by tumour size, patients with intrahepatic cholangiocarcinomas smaller than two centimetres achieved five-year overall and recurrence-free survival of 80 percent, squarely in line with the international data underpinning the current ILTS guidance. By contrast, patients with perihilar tumours fared far worse, with five-year overall survival of just 31 percent and recurrence-free survival of 40 percent, significantly inferior to the intrahepatic group.

The statistical analysis sharpened these contrasts further. Univariate Cox regression identified age, known pre-transplant tumours, mixed histological type and poorly differentiated tumours as factors associated with poorer overall survival. When variables with p values below 0.20 were carried into a multivariate model, only one factor remained independently significant: poorly differentiated tumours, which carried a hazard ratio of 4.78 for death compared with better-differentiated cancers. The authors suggest this finding could eventually inform pre-transplant decision making, since a biopsy demonstrating poorly differentiated cholangiocarcinoma might steer a patient toward a different treatment path, though they caution that the role of pre-operative biopsies in risk stratification requires further study.

The mixed hepatocellular-cholangiocarcinomas deserve particular attention, because clinical outcomes after transplantation for these tumours have never been clearly established. All 17 mixed tumours in this cohort were detected incidentally on explant histology, and none were knowingly transplanted, a reflection of how difficult these cancers are to diagnose before surgery. Radiologically, mixed tumours cannot be reliably distinguished from pure hepatocellular carcinoma, and neither biopsies nor tumour markers such as alpha-fetoprotein and CA19-9 carry sufficient sensitivity, since elevated levels of both may reflect the biphenotypic nature of the neoplasm. Yet the survival data was unexpectedly reassuring: five-year overall survival for the mixed group was 68 percent, significantly better than the 51 percent for pure cholangiocarcinomas, and comparable to the 70 percent reported in a multi-centre American study of 67 patients transplanted for mixed tumours within Milan criteria.

The authors are candid about the limitations of their work. The study is retrospective, spanning an era in which clinical practice has changed enormously, and not every data point was available for every patient, which affected the completeness of the statistical analysis. Significant heterogeneity also exists within the cohort, mixing knowingly transplanted perihilar and intrahepatic tumours with incidental discoveries and the mixed histological subtype. Still, the central conclusion stands: the international guidance on very early intrahepatic cholangiocarcinoma does apply to Australia and New Zealand, and patients transplanted with cirrhosis and tumours under two centimetres can expect excellent five-year survival. As transplant oncology expands and demand for donor organs grows, audits like this one provide the regional evidence needed to decide, ethically and practically, who should receive a scarce and precious liver.

Subject of Research: Liver transplantation outcomes for cholangiocarcinoma and mixed hepatocellular-cholangiocarcinoma in Australia and New Zealand

Article Title: COMIT-ANZ: an audit of cholangiocarcinoma and mixed hepatocellular carcinoma-cholangiocarcinoma outcomes for patients undergoing liver transplantation in Australia and New Zealand

Article References: Riddiough, G. E., Hall, K., Byrne, M., Brown, K., Kilburn, D., Goh, S. K., Marshall-Webb, M., Pulitano, C., Chan, K., Philipoff, A., Nazaar, A., & Lee, E. (2026). COMIT-ANZ: an audit of cholangiocarcinoma and mixed hepatocellular carcinoma-cholangiocarcinoma outcomes for patients undergoing liver transplantation in Australia and New Zealand. Frontiers in Transplantation, 5, Article 1856922. https://doi.org/10.3389/frtra.2026.1856922

Image Credits: AI Generated

DOI: 10.3389/frtra.2026.1856922

Keywords: liver transplantation, cholangiocarcinoma, transplant oncology, mixed hepatocellular-cholangiocarcinoma, intrahepatic cholangiocarcinoma, survival outcomes, Australia New Zealand, ILTS guidance, COMIT-ANZ, audit, mixed, hepatocellular

The core problem is anatomical and biological. Cholangiocarcinoma is classified into intrahepatic, perihilar, and distal subtypes, each with distinct growth behavior. Intrahepatic tumors may appear as mass-forming lesions, as periductal infiltrating growth that creeps along the bile duct wall, or as papillary tumors growing inside the duct lumen. Perihilar and distal tumors, which make up the majority of cases in referral centers, typically present as infiltrative sclerosing strictures with longitudinal subepithelial spread rather than as discrete masses. This morphological diversity means that a technique excellent at sampling one subtype may be nearly useless for another. Moreover, the tumor is characterized by abundant desmoplastic stroma, a dense fibrotic reaction composed of cancer-associated fibroblasts, inflammatory cells, and a collagen-rich extracellular matrix that often constitutes a substantial proportion of the tumor volume. The result is tissue with relatively few malignant cells, which explains why conventional sampling techniques so often return inadequate or nonrepresentative specimens.

The numbers tell a sobering story. A landmark meta-analysis by Navaneethan and colleagues found that the pooled sensitivity of brush cytology for detecting malignant biliary strictures is only about 45 percent, while intraductal forceps biopsy reaches roughly 48 percent. Combining both methods raises sensitivity to only about 59 percent, even though specificity remains excellent at approximately 99 percent. In practical terms, this means that a negative cytology or histology result cannot reliably exclude malignancy, forcing clinicians to repeat procedures or pursue multimodal evaluation before committing to surgery or systemic therapy. Fluorescence in situ hybridization, which detects chromosomal abnormalities associated with biliary malignancy, can improve matters considerably; adding FISH to brush cytology and biopsy has achieved diagnostic sensitivities approaching 82 percent in selected populations. But the field has been waiting for techniques that yield higher-quality tissue and greater diagnostic confidence from the outset.

Enter endoscopic ultrasound, or EUS, which has evolved over three decades from a purely imaging modality into a comprehensive diagnostic and interventional platform. Because the echoendoscope sits in close proximity to the biliary system, it can detect subtle pathological changes invisible on computed tomography or magnetic resonance imaging, particularly in small distal lesions and early-stage disease. Research shows that EUS outperforms CT and MRCP in distinguishing malignant from benign biliary strictures, with reported sensitivities ranging from 25 to 91 percent and specificities from 89 to 100 percent. Beyond imaging, EUS enables real-time tissue acquisition from primary tumors, regional lymph nodes, and metastatic lesions in a single procedure, and studies have reported up to 85 percent accuracy in assessing vascular invasion, a critical factor in determining whether a tumor can be surgically resected. The introduction of fine-needle biopsy needles, which provide core tissue with preserved architecture rather than mere cytology, has been transformative: these specimens are suitable not only for histopathological examination but also for immunohistochemistry and next-generation sequencing.

That last point matters enormously in the era of precision oncology. Comprehensive genomic profiling has revealed that cholangiocarcinoma is a molecularly heterogeneous disease harboring several actionable alterations, including FGFR2 fusions, IDH1 mutations, HER2 amplification, BRAF V600E mutations, NTRK fusions, and microsatellite instability. Targeted therapies directed against these biomarkers have markedly expanded treatment options for selected patients, and international guidelines now recommend molecular profiling in unresectable or metastatic disease whenever adequate tissue is available. EUS-guided fine-needle biopsy has become an important platform for this work, with several studies demonstrating that it yields a higher proportion of samples suitable for complete genomic profiling while reducing the need for repeat tissue acquisition. In other words, the same needle that establishes the diagnosis can also determine which drug the patient should receive.

But EUS has a blind spot: infiltrative tumors that do not form a solid, defined mass are difficult to identify and sample under ultrasound guidance, particularly in the perihilar region. This is where digital single-operator cholangioscopy enters the picture. Systems such as the SpyGlass DS allow the endoscopist to steer a tiny camera directly into the bile duct, visualizing the mucosal surface in real time. Characteristic features suggestive of malignancy include irregular mucosal nodularity, papillary projections, ulceration, and dilated tortuous vessels, with abnormal neovascularization being one of the most reliable visual indicators. A meta-analysis by de Oliveira and colleagues, encompassing 283 patients undergoing digital single-operator cholangioscopy, demonstrated a pooled sensitivity of 94 percent and specificity of 95 percent for visual impression alone. In patients with prior nondiagnostic ERCP-based sampling, visual assessment achieved sensitivities of 90 to 100 percent and overall diagnostic accuracy approaching 97 percent. Cholangioscopy-directed biopsy, meanwhile, achieves tissue adequacy in about 93 percent of cases with sensitivity around 75 percent and specificity of 100 percent according to a large multinational registry.

The Bulgarian team, led by Petko Karagyozov, Nadica Male, Kalina Panova, and Stela Nikolova at Acibadem City Clinic University Hospital Tokuda in Sofia, put these complementary techniques to the test in a retrospective single-center analysis of 117 consecutive patients evaluated for suspected biliary malignancy between January 2020 and September 2025. Following surgical histopathology or multidisciplinary consensus, 96 patients, or 82 percent, were confirmed to have malignant disease, with perihilar lesions predominating at 78 percent. EUS-guided fine-needle biopsy was performed in 40 patients with confirmed malignancy, achieving a sensitivity of 65 percent, a figure the authors attribute to the predominance of infiltrative hilar lesions lacking a clear sonographic target. Cholangioscopy-directed biopsy was performed in 72 malignant cases, achieving a sensitivity of 72.2 percent, while characteristic cholangioscopic visual features were identified in 61 of those patients, corresponding to a sensitivity of 84.7 percent.

The most striking result emerged in the subgroup of 26 patients who underwent both procedures. When evaluated individually, each modality demonstrated only moderate sensitivity, but combining the two approaches increased overall sensitivity to 96.2 percent, with only a single malignant lesion remaining undiagnosed after the combined endoscopic evaluation. This finding aligns with previous work: Lee and colleagues reported a combined sensitivity of 100 percent for EUS-FNA plus cholangioscopy-guided biopsy, while Moura and colleagues achieved 86 percent with EUS-FNA plus ERCP-based sampling. Both procedures in the Bulgarian cohort demonstrated an acceptable safety profile, with mild pancreatitis occurring in 4.5 percent of patients after EUS and cholangitis in 13.5 percent after cholangioscopy, all classified as mild and resolved with conservative treatment. No severe adverse events or procedure-related mortality were observed.

The authors are careful to frame these findings as exploratory and hypothesis-generating rather than definitive. The study was retrospective and single-center, the choice of diagnostic modality was individualized according to clinical judgment rather than a standardized protocol, and the combined-modality subgroup comprised only 26 patients. Formal paired statistical comparisons between the two techniques were not performed, and detailed procedural characteristics such as needle type and gauge were not consistently available. Nevertheless, the cohort reflects real-world clinical practice at a tertiary referral center, precisely the setting where diagnostic uncertainty is greatest and multimodal evaluation is most likely to provide meaningful benefit. The authors emphasize that the choice of endoscopic approach should be tailored to lesion morphology and anatomical location: patients with discrete mass lesions or suspected nodal disease benefit most from EUS, whereas infiltrative strictures without an identifiable mass are better evaluated with cholangioscopy.

Looking ahead, the diagnostic landscape is evolving rapidly beyond the endoscope itself. Artificial intelligence and machine learning algorithms are being developed to assist in interpreting EUS images and identifying malignant cholangioscopic features, potentially reducing interobserver variability and supporting real-time decision-making. Probe-based confocal laser endomicroscopy enables real-time microscopic assessment of the biliary epithelium during ERCP, while radiomics and radiogenomic approaches are extracting quantitative imaging biomarkers from CT, MRI, and EUS examinations. Liquid biopsy, analyzing circulating tumor DNA, circulating tumor cells, microRNAs, and extracellular vesicles, offers the promise of minimally invasive diagnosis and longitudinal monitoring of treatment response, particularly valuable in patients with limited tissue availability. The ultimate vision, according to the authors, is an integrated diagnostic algorithm that combines high-resolution imaging, endoscopic visualization, targeted tissue acquisition, molecular profiling, and computational decision support, tailored to each patient’s tumor morphology, anatomical location, and molecular characteristics. For a cancer that has resisted diagnosis for decades, the message is clear: no single lens is enough, but two lenses looking from different directions may finally bring the tumor into focus.

Subject of Research: Multimodal endoscopic diagnosis in biliary oncology: integrating EUS-guided tissue acquisition and cholangioscopy for personalized cancer care

Article Title: Multimodal endoscopic diagnosis in biliary oncology: integrating EUS-guided tissue acquisition and cholangioscopy for personalized cancer care

Article References: Karagyozov, P., Male, N., Panova, K., & Nikolova, S. (2026). Multimodal endoscopic diagnosis in biliary oncology: integrating EUS-guided tissue acquisition and cholangioscopy for personalized cancer care. Frontiers in Gastroenterology, 5, Article 1924535. https://doi.org/10.3389/fgstr.2026.1924535

Image Credits: AI Generated

DOI: 10.3389/fgstr.2026.1924535

Keywords: cholangiocarcinoma, endoscopic ultrasound, cholangioscopy, precision oncology, biliary cancer, diagnostic endoscopy, molecular profiling, Multimodal, endoscopic, diagnosis, biliary, oncology

For decades, cancer pharmacology has depended on two-dimensional monolayer cultures, in which tumor cells grow as flat sheets on plastic. These systems are cheap, fast, and easy to standardize, which explains their enduring popularity. Yet they systematically strip away the features that make real tumors hard to kill. In a monolayer, every cell receives equal access to nutrients, oxygen, and drug molecules, and there is no architecture to speak of. In a living tumor, by contrast, cells are packed into dense three-dimensional masses where oxygen levels fall steeply, waste accumulates, and blood-borne drugs must traverse layers of extracellular matrix and multiple cell populations before reaching their targets.

The review, which surveys the evidence base for biliary tract cancer research specifically, contends that this architectural fidelity is not a cosmetic detail but a decisive determinant of drug response. Three-dimensional tumor models recreate physiological barriers that are absent from flat cultures, including hypoxia-driven metabolic reprogramming, dense extracellular matrix shielding, and gradients of drug distribution. Each of these factors can independently reduce the effective concentration of a chemotherapeutic agent inside the tumor, and in combination they help explain why compounds that look potent in the dish collapse in the clinic.

Hypoxia deserves particular attention. When tumor regions are starved of oxygen, cancer cells shift their metabolism toward glycolysis, alter their redox balance, and activate transcriptional programs that favor survival under stress. This metabolic reprogramming is well documented to blunt the activity of drugs whose mechanisms depend on cellular proliferation or on the generation of reactive oxygen species. Flat cultures simply cannot generate the oxygen gradients that trigger these adaptations, so the resistance phenotypes they would reveal remain invisible to conventional screening pipelines.

The extracellular matrix presents a parallel problem. In biliary tract cancers, desmoplastic stromal reactions produce a dense fibrotic matrix that physically impedes drug penetration while simultaneously delivering survival signals to embedded tumor cells. Three-dimensional scaffolds and spheroid systems can be engineered to reproduce this fibrotic environment, allowing researchers to measure how deeply a given agent permeates the tumor mass and how matrix-associated signaling changes the thresholds for cell death. The review emphasizes that this so-called multicellular resistance is a property of the tumor as a system, not of individual cells, which is precisely why it evaporates in monolayer experiments.

At the molecular heart of chemoresistance in these cancers lies the evasion of apoptosis, the canonical programmed cell death pathway that most cytotoxic drugs are designed to trigger. The review highlights dysregulation of the Bcl-2 protein family rheostat, a balance between pro-death and pro-survival members that determines whether a cell commits to apoptosis after suffering drug-induced damage. In three-dimensional models, biliary tract cancer cells show heightened dependence on anti-apoptotic guardians such as Bcl-xL and Mcl-1, proteins that buffer the cell against mitochondrial outer membrane permeabilization. This dependence profile is far more informative than bulk viability assays, because it points directly toward rational drug combinations, for example pairing chemotherapy with selective Mcl-1 or Bcl-xL inhibitors.

Beyond apoptosis, the three-dimensional context provides a far more faithful setting for investigating alternative cell death modalities. Ferroptosis, an iron-dependent form of death driven by lipid peroxidation, and necroptosis, a regulated necrotic pathway, have attracted intense interest as ways to kill tumor cells that have learned to block apoptosis. The review argues that the metabolic states, oxygen tensions, and matrix interactions present in 3D cultures substantially change how these pathways are engaged, meaning that ferroptosis- and necroptosis-inducing agents must be evaluated in architectures that resemble real tumors rather than in cells flattened on plastic.

Another resistance reservoir that only architecture-dependent models can expose is the population of quiescent cancer stem cells sheltered within specialized niches. These slowly dividing cells are thought to survive chemotherapy and later seed relapse, but in a monolayer most cells cycle actively and the stem-like state is poorly maintained. Three-dimensional organoid and spheroid systems preserve niche signaling, allowing researchers to identify the dormant subpopulations, characterize the signals that protect them, and test strategies aimed at flushing them out of quiescence before or during treatment.

The most clinically ambitious application of these platforms involves patient-derived organoids, miniature tumors grown from a patient’s own tissue that retain the genetic, epigenetic, and architectural features of the original malignancy. The review frames such organoids as high-fidelity clinical avatars: they can be screened against panels of drugs and combinations in vitro, and the results used to guide precision oncology decisions for the individual patient. For a disease like biliary tract cancer, where molecular heterogeneity is wide and effective targeted options remain limited, the prospect of testing regimens on a personalized tumor replica before committing the patient to toxicity is a compelling translational goal.

The authors are careful to keep the promise of 3D models in perspective. Two-dimensional culture limitations are only one component of a broader translational pipeline that also includes animal models, gaps in biomarker development, and the anatomical challenges of treating tumors in the bile ducts and liver. Outstanding problems include standardizing culture protocols so that results can be compared across laboratories, integrating functional immune components into the models, and scaling production to industrial screening volumes. Even so, the central message is unambiguous: if researchers want to understand why gemcitabine and cisplatin fail, and to design combinations that overcome that failure, the tumors must be studied in three dimensions. Adopting these physiologically relevant systems, the review concludes, is imperative for dismantling the profound chemoresistance that has long defined biliary tract cancer.

Subject of Research: Drug resistance and apoptosis evasion in biliary tract cancers studied with 3D tumor models

Article Title: Decoding drug resistance and apoptosis in biliary tract cancers using 3D tumor models

Article References: Gill, G. S., Sahoo, O. S., Nayek, A., Sarkar, S. K., Kurdia, K. C., Bhardwaj, N., Das, C. J., Galodha, S., Goyal, G., Karmakar, S., & Dhar, R. (2026). Decoding drug resistance and apoptosis in biliary tract cancers using 3D tumor models. Frontiers in Cell Death, 5, Article 1819303. https://doi.org/10.3389/fceld.2026.1819303

Image Credits: AI Generated

DOI: 10.3389/fceld.2026.1819303

Keywords: biliary tract cancer, cholangiocarcinoma, gallbladder cancer, drug resistance, apoptosis, 3D tumor models, patient-derived organoids, hypoxia, extracellular matrix, Bcl-2, ferroptosis, precision oncology

The study, led by Xiang Pan and Ziting Su of the First Affiliated Hospital of Dali University in Yunnan, China, and published in BMC Cancer, systematically evaluated clinical practice guidelines on precision oncology in biliary tract cancers using two internationally recognised appraisal instruments, AGREE II and AGREE-REX. The team searched eight databases and thirteen guideline repositories and society websites, capturing guidance published or updated between January 2016 and June 2026. From thirty individual reports, the researchers assembled twenty-seven distinct guideline families, which they then subjected to independent appraisal by three trained assessors.

What makes this analysis technically distinctive is the decision to separate two halves of the precision oncology pathway that guidelines frequently blur together: molecular testing and biomarker-directed treatment. The authors argue that precision medicine in biliary tract cancer requires more than merely listing actionable biomarkers. A complete guideline must connect the who and how of testing to the treatment or clinical trial action that follows a positive result. By applying separate AGREE-REX appraisal clusters for testing and treatment recommendations, and by mapping cross-guideline support across a prespecified twelve-topic matrix, the team created one of the most granular portraits to date of how well guidance documents serve the full genomic care pathway.

The AGREE II results reveal a striking asymmetry in guideline quality. The strongest domain was clarity of presentation, with a median score of 98.1 percent, followed by scope and purpose at 88.9 percent. In other words, when a guideline makes a recommendation, it usually states it clearly. But the infrastructure around those recommendations was consistently weaker. Patient and public involvement, methods for updating, monitoring and audit provisions, and external review all scored poorly across the field. These are the domains that determine whether a guideline remains trustworthy as evidence evolves, whether it reflects what patients actually value, and whether institutions can verify that recommendations are being followed in practice.

The AGREE-REX appraisal, which drills down to the quality of individual recommendations rather than whole documents, surfaced another weakness: values and preferences was the lowest-scoring domain in both the testing and treatment clusters. This finding suggests that guideline developers are not systematically describing the evidence underlying patient values and treatment preferences when they craft recommendations. For patients facing choices between cytotoxic chemotherapy, targeted agents, or clinical trial enrolment, that gap is more than an academic shortcoming.

On the substantive question of which biomarkers enjoy the broadest guideline support, the picture is clear. Broad molecular profiling using next-generation sequencing was supported by eighteen of twenty-seven guideline families, reflecting a growing consensus that comprehensive genomic testing, rather than single-gene assays, is the appropriate strategy in this disease. On the treatment side, the highest support went to microsatellite instability-high or mismatch repair-deficient tumours, endorsed by twenty of twenty-seven families, followed by FGFR2 alterations at seventeen and IDH1 mutations at sixteen. HER2-directed therapy was supported by twelve of twenty-six families after one unclassifiable unit was excluded. These targets map directly onto approved therapies and the antibody-drug conjugates now reshaping the treatment landscape for HER2-positive disease.

Perhaps the most consequential finding is that testing and treatment support frequently diverged. Several biomarker-treatment pairings were endorsed as therapies without corresponding guidance on molecular testing, and vice versa. A clinician reading one of these guidelines might learn that an IDH1 inhibitor is appropriate for a patient with an IDH1-mutant tumour, yet find no recommendation on how or when to test for that mutation. The authors are careful to note that such divergent coverage does not itself indicate lower recommendation quality; rather, it reveals structural incompleteness. Guidelines excel at the endpoint of the pathway while leaving the intermediate steps, the testing indications, timing, and methods, underspecified.

The review also demonstrates methodological rigour in its own appraisal process. Historical intraclass correlation coefficients across the appraisal rounds ranged from 0.918 to 0.960, indicating near-perfect agreement among the three independent assessors. A separate revision-stage sensitivity analysis incorporating de novo ratings for a subset of twenty-two families yielded a coefficient of 0.925. Sensitivity analyses that counted clinical-trial-only recommendations alongside explicit and conditional recommendations further tested the robustness of the coverage findings. The study was prospectively registered with PROSPERO under registration number CRD420261438683, and the search strategy was peer-reviewed according to the PRESS standard.

The implications for clinical practice are immediate. Biliary tract cancers are diagnosed in roughly hundreds of thousands of people worldwide each year, and outcomes remain poor, with many patients presenting at advanced stages where molecularly informed decisions carry the greatest weight. For oncologists navigating this landscape, the review functions as a meta-map: it identifies which guidelines provide the most complete testing-to-treatment pathways and where the consensus on targets such as MSI-H/dMMR, FGFR2, and IDH1 is strongest. It also flags where clinicians must supplement guideline advice, for instance by consulting molecular tumour boards or trial registries when testing guidance is absent.

For guideline developers, the authors offer a clear blueprint for the next generation of documents. Future guidance, they conclude, should explicitly link testing indication, timing, and method to post-test clinical action, while strengthening patient involvement, evidence-to-decision reporting, resource-sensitive implementation strategies, audit indicators, conflict of interest management, and prospective updating mechanisms. The finding that no external funding supported the research, with study expenses personally covered by the corresponding author, adds a note of independence to a field where commercial interests in genomic testing and targeted therapies are considerable. As precision oncology matures, the bottleneck may no longer be discovering new biomarkers but ensuring that the documents meant to translate them into bedside decisions are as rigorous, complete, and current as the science they describe.

Subject of Research: Quality appraisal of clinical practice guidelines for precision oncology in biliary tract cancers

Article Title: Quality of clinical practice guidelines on precision oncology in biliary tract cancers: a systematic review using AGREE II and AGREE-REX

Article References: Pan, X., An, Q., Liu, J., Zhang, S., Long, Y., Jiang, J., & Su, Z. (2026). Quality of clinical practice guidelines on precision oncology in biliary tract cancers: a systematic review using AGREE II and AGREE-REX. BMC Cancer. https://doi.org/10.1186/s12885-026-17168-8

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17168-8

Keywords: biliary tract cancer, precision oncology, clinical practice guidelines, AGREE II, AGREE-REX, cholangiocarcinoma, next-generation sequencing, FGFR2, IDH1, MSI-H/dMMR, HER2, systematic review

The trial, known as KEYNOTE-966, enrolled 1,069 patients between October 2019 and June 2021 across 175 medical centres in the Asia-Pacific region, Europe, North America and South America. Participants had untreated, histologically confirmed unresectable locally advanced or metastatic biliary tract cancer, including extrahepatic cholangiocarcinoma, gallbladder cancer and intrahepatic cholangiocarcinoma. They were randomly assigned in equal measure to receive either pembrolizumab or a saline placebo alongside standard gemcitabine and cisplatin, with neither patients nor treating investigators knowing which arm they occupied. Pembrolizumab, an antibody that blocks the programmed cell death protein 1, or PD-1, receptor on T cells, is designed to release a molecular brake that tumours exploit to evade immune destruction.

When the protocol-specified final analysis was reported, with a median follow-up of 25.6 months, the pembrolizumab combination had delivered a statistically significant and clinically meaningful improvement in overall survival: a median of 12.7 months compared with 10.9 months for chemotherapy plus placebo, corresponding to a 17 percent reduction in the risk of death. The new report, published in eClinicalMedicine, extends that picture with a median study follow-up of 36.6 months, roughly eleven months of additional observation. At the updated data cutoff of November 2023, median overall survival remained 12.7 months in the pembrolizumab group versus 10.9 months in the placebo group, with a hazard ratio of 0.86, indicating that the survival advantage persisted essentially undiminished over time.

The longer follow-up also sharpened the portrait of long-term survivors. At 24 months, an estimated 25 percent of patients in the pembrolizumab arm were alive compared with 19 percent in the control arm; at 36 months the figures were 13 percent and 11 percent respectively. Approximately 15 percent of participants in both groups remained alive beyond three years, a striking finding in a disease where metastatic five-year survival has historically languished below 5 percent. The investigators caution that the number of patients still at risk in the tail of the survival curves is small, making precise comparisons at these late time points difficult, but the persistence of a hazard ratio favouring pembrolizumab throughout follow-up suggests the treatment benefit is genuinely preserved rather than an artefact of early curve separation.

Progression-free survival, the time until disease worsens or death, also continued to favour the immunotherapy combination, with a median of 6.5 months versus 5.6 months and a hazard ratio of 0.85. Interestingly, the objective response rate, the proportion of patients whose tumours shrank measurably, was identical between arms at 29 percent, a reminder that in immunotherapy the most meaningful gains often come not from shrinking more tumours but from controlling them for longer. That interpretation is borne out by the duration of response: among patients who did respond, responses lasted a median of 8.3 months with pembrolizumab versus 6.9 months with placebo, and at 24 months, 18 percent of responses in the pembrolizumab arm were still ongoing compared with just 7 percent in the placebo arm. The number of patients completing the full 35 cycles, roughly two years, of pembrolizumab also grew since the final analysis, while no comparable increase occurred in the placebo group.

Safety data accumulated over the extended follow-up brought no unpleasant surprises. Nearly all patients in both arms experienced some adverse event, most commonly the neutropenia and anaemia expected from cisplatin-based chemotherapy, and the rates of severe grade 3 or 4 events remained stable at around 70 percent in each group. Immune-mediated adverse events, the characteristic toxicities of checkpoint inhibitors, arose in 25 percent of pembrolizumab recipients versus 15 percent of placebo recipients, with hypothyroidism and pneumonitis the most frequent. Six additional patients in the pembrolizumab arm experienced severe immune-mediated events during the extended follow-up, including gastritis, haemolytic anaemia and single cases of colitis, hepatitis, hypophysitis and pneumonitis, but the overall profile remained comparable to the final analysis, with no new safety signals identified. Deaths attributable to treatment-related events were unchanged at 2 percent in the pembrolizumab group.

The updated results land alongside three-year data from the rival TOPAZ-1 trial, which tested a different checkpoint inhibitor, durvalumab, an antibody targeting PD-L1 rather than PD-1, on the same chemotherapy backbone. TOPAZ-1 reported a hazard ratio of 0.74 for overall survival, with medians of 12.9 versus 11.3 months, after a median follow-up of 41.3 months. The two trials differ in instructive ways: TOPAZ-1 limited gemcitabine to eight cycles whereas KEYNOTE-966 allowed it to continue until progression or intolerance, and KEYNOTE-966 was larger, with 1,069 participants compared with 685, including substantially more patients enrolled outside Asia. Notably, the survival benefit in KEYNOTE-966 was consistent in the large non-Asian subgroup, strengthening confidence that the finding generalises across diverse populations and healthcare systems.

Quality-of-life analyses, reported previously from the trial, add an important dimension: adding pembrolizumab to the chemotherapy regimen did not produce a clinically meaningful deterioration in patient-reported functioning or well-being. The authors of the new analysis acknowledge a caveat here, namely that existing quality-of-life instruments were largely designed for cytotoxic drugs and may not fully capture the distinct experience of immune-mediated toxicities, and they call for better standardisation of patient-reported outcome assessment in future biliary tract cancer trials so that survival gains can be weighed against the lived experience of treatment.

The study is not without limitations. Because the primary survival endpoint was already met at the final analysis, the updated comparisons are descriptive and exploratory, with no formal hypothesis testing or alpha allocation. The shrinking at-risk population with longer follow-up makes late survival estimates imprecise, and the biological characteristics that distinguish the long-term survivors, whether tumour molecular features, disease burden, or responses to subsequent therapies, were not specifically evaluated. The authors argue that characterising this favourable subgroup could inform future patient selection and point the way toward rational combinations with novel agents, an urgent priority given how poor the prognosis remains even with immunotherapy on board.

Nevertheless, the message for clinical practice is clear and now firmly anchored in three years of evidence: pembrolizumab plus gemcitabine and cisplatin stands as a validated standard first-line treatment for previously untreated unresectable or metastatic biliary tract cancer. Together with TOPAZ-1, the trial establishes that immune checkpoint blockade has earned a permanent place in the frontline management of one of medicine’s deadliest cancers, converting a uniformly grim prognosis into one where a meaningful minority of patients can now anticipate years, not months, of survival.

Subject of Research: Long-term phase 3 trial results of pembrolizumab combined with gemcitabine and cisplatin chemotherapy for advanced biliary tract cancer

Article Title: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial

Article References: Ueno, M., Yoo, C., Ren, Z., Furuse, J., Kelley, R. K., Chan, S. L., Edeline, J., Klümpen, H.-J., Yau, T., Verslype, C., Ozaka, M., Bouattour, M., Park, J. O., Vogel, A., Valle, J. W., Starkopf, L., Malhotra, U., Siegel, A. B., Qin, S., … Elias, R. (2026). Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial. eClinicalMedicine, 100, Article 104213. https://doi.org/10.1016/j.eclinm.2026.104213

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104213

Keywords: biliary tract cancer, cholangiocarcinoma, pembrolizumab, KEYNOTE-966, immunotherapy, PD-1 inhibitor, gemcitabine, cisplatin, phase 3 trial, overall survival, checkpoint inhibitor, oncology

The problem is rooted in the biology and anatomy of these tumours. Brush cytology and forceps biopsy taken during ERCP sample only a small fraction of the stricture, and desmoplastic stroma often surrounds sparse malignant cells, so malignant strictures can yield false negatives. Serum carbohydrate antigen 19-9, the most widely used blood marker, is also unreliable in this setting: cholestasis itself, the bile-flow obstruction that brings patients to endoscopy in the first place, can push CA19-9 concentrations above the usual 44 U/mL cutoff even when no cancer is present. The result is a diagnostic limbo in which patients undergo repeated procedures, delayed referrals and, in the worst cases, missed opportunities for resection.

A study published in eGastroenterology by Rojo and colleagues at the First Hospital of Jilin University proposes a strikingly simple way to extract more information from a procedure patients already undergo: sequence the bile. Bile collected during routine ERCP is ordinarily treated as waste, but it bathes the tumour and is rich in cell-free DNA, fragments of genetic material shed by dying cells. Because malignant cells in the ductal epithelium and pancreas release their DNA directly into this fluid, bile offers a far more concentrated and anatomically relevant source of tumour DNA than peripheral blood, where pancreatobiliary cancer DNA is heavily diluted.

The technical elegance of the approach lies in its economy. Rather than deep sequencing, the team used ultra-low-pass whole-genome sequencing, or ULP-WGS, reading the bile cell-free DNA at roughly 0.2× genomic coverage from as little as 2 nanograms of starting material. At such shallow depth, individual bases cannot be reliably called, but the method does something arguably more useful: it reveals large-scale copy-number alterations, the gains and losses of whole chromosome arms that are hallmarks of cancer genomes. Using the open-source ichorCNA pipeline, the researchers computed a tumour fraction, the estimated proportion of cell-free DNA derived from tumour, with a threshold of 10 per cent or more indicating detectable circulating tumour DNA. Reducing sequencing depth from the conventional 30–50× used in clinical whole-genome sequencing to 0.2× was estimated to cut sequencing costs by approximately 130- to 215-fold, a difference that could make the test scalable in routine practice.

The prospective cohort comprised 95 patients undergoing their first ERCP for a biliary stricture that was radiologically suspicious for malignancy. At the outset, pathological assessment classified 26 strictures as malignant and 69 as indeterminate. Over follow-up of up to 12 months, 45 of the initially indeterminate cases were confirmed malignant and 24 proved benign, giving a final malignant cohort of 40 cholangiocarcinomas and 31 pancreatic ductal adenocarcinomas. This design mirrors the real clinical dilemma, since the patients who matter most are precisely those in whom the first pathological evaluation fails to settle the question.

The performance figures are encouraging on both ends of the spectrum. Among patients already diagnosed with malignancy at the first ERCP, bile ULP-WGS detected tumour DNA in 73 per cent of cases, including 82 per cent of cholangiocarcinomas and 56 per cent of pancreatic cancers. More importantly, in the initially indeterminate strictures later confirmed as malignant, sensitivity was 51 per cent, while 23 of the 24 ultimately benign cases tested negative, corresponding to a specificity of 96 per cent. By comparison, CA19-9 at the prespecified threshold of 44 U/mL achieved only 53 per cent specificity in evaluable benign cases, underscoring how poorly the conventional marker performs in the obstructed, inflamed patients who need clarity most.

The most clinically compelling finding concerns timing. In the 23 patients whose malignancy was not established at the first ERCP but whose bile tested positive, tumour DNA was detected a median of 38 days before the conventional diagnosis was made. In seven patients the genomic signal preceded diagnosis by more than 100 days, and in one case by an extraordinary 499 days. For cancers in which every week of delay can shift a patient from resectable to unresectable disease, a lead time measured in months could translate directly into surgical candidacy and survival. The researchers also compared their shallow approach with a targeted next-generation sequencing assay of 52 genes, dubbed Bilemut, which detected mutations in 94.7 per cent of evaluable malignant strictures and remained more sensitive overall. ULP-WGS, however, required less DNA and delivered genome-wide copy-number information that targeted mutation panels cannot capture, suggesting the two methods are complementary rather than competing.

Beyond detecting cancer, the copy-number profiles carried information about where the tumour had arisen. The bile-derived alterations reproduced genomic patterns previously described in pancreatobiliary tumour tissue, including recurrent losses of chromosome arms 9p, 17p and 18q and gains of 7p, 7q, 8q and 19q. A supervised classifier built on 50 copy-number regions distinguished cholangiocarcinoma from pancreatic ductal adenocarcinoma with 86.4 per cent accuracy in the reference cohort and 85.0 per cent in a separate validation cohort. Loss of 1p was enriched in pancreatic cancer, whereas 9p loss occurred more frequently in cholangiocarcinoma. This matters because the two tumours demand different management, from neoadjuvant strategies to surgical planning, and tissue-of-origin assignment from a liquid biopsy could guide decisions even before a formal histological diagnosis exists.

The sequencing data also appeared to carry prognostic weight. Neither tumour fraction alone nor targeted tumour mutational burden alone significantly stratified overall survival, but the combination did. Patients who were both tumour-fraction positive and carried mutations in at least three genes had a median overall survival of 5.1 months, compared with 13.7 months among the remaining patients. After adjustment for initial management, CA19-9 and carcinoembryonic antigen, this combined genomic profile remained independently associated with poorer survival, with an adjusted hazard ratio of 2.51 and a 95 per cent confidence interval of 1.22 to 5.14. If validated, such a signature could help clinicians identify patients whose disease course is likely to be aggressive and for whom early referral to palliative or intensified protocols might be appropriate.

The authors are careful about the limits of their test. A negative bile ULP-WGS result is not sensitive enough to exclude malignancy, and the method should not replace histopathology, which remains the diagnostic gold standard. Its most promising role is as a complementary test after an inconclusive first ERCP: a positive result could justify accelerated repeat sampling, cholangioscopy with directed biopsy, endoscopic ultrasound-guided tissue acquisition or closer multidisciplinary surveillance, while sparing patients with negative results some of the cascade of repeat procedures. The study also has constraints that temper enthusiasm. It was conducted at a single centre, the cohort was modest, the ultimately benign group was small, and the cholangiocarcinoma-versus-pancreatic-cancer classifier requires external validation before it can inform real-world decisions. Prospective multicentre studies must now determine whether bile genomics can genuinely shorten diagnostic delays, reduce the number of invasive repeat procedures and, ultimately, improve outcomes for patients caught in the diagnostic grey zone of the biliary stricture. What the current work establishes, however, is that a fluid routinely discarded at the end of every ERCP contains a readable, cost-effective genomic record of the tumours it touches, and that reading it may move pancreatobiliary cancer diagnosis weeks or even months earlier.

Subject of Research: Ultra-low-pass whole-genome sequencing of bile cell-free DNA for detecting and classifying malignant biliary strictures

Article Title: Bile genome sequencing may accelerate diagnosis of malignant biliary strictures

Article References: Bile genome sequencing may accelerate diagnosis of malignant biliary strictures. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bile cell-free DNA, ultra-low-pass whole-genome sequencing, biliary strictures, cholangiocarcinoma, pancreatic ductal adenocarcinoma, ERCP, copy-number alterations, tumour fraction, liquid biopsy, CA19-9, early cancer diagnosis, eGastroenterology

The review, led by Weibin Zhang and Lingmei Kong of a Chinese research team, focuses on the tumor stroma, the dense structural scaffold that surrounds and supports cancer cells. In cholangiocarcinoma, this stroma is pathologically distinctive, marked by severe fibrosis, sparse blood vessels, and a strongly immunosuppressive character. Far from being a passive framework, the stroma is now understood to be an active participant in tumor biology. It is packed with extracellular matrix proteins, cancer-associated fibroblasts, hepatic stellate cells, mesenchymal stem cells, and a collection of immune cells that largely work in the tumor’s favor. Among the many matrix components, collagen types I, III, and VI dominate the fibrotic landscape, and it is the sixth type, built in part from the COL6A1 gene’s product, that the authors identify as a potentially decisive regulator of how the tumor grows, invades, and evades treatment.

COL6A1, located on chromosome 21q22.3, encodes the alpha-1 chain of type VI collagen, a polypeptide of 1,028 amino acid residues with a relative molecular mass of approximately 108.5 kilodaltons. This chain pairs with the alpha-2 and alpha-3 chains, also encoded by separate genes, to form the heterotrimeric functional unit of type VI collagen. These trimers further assemble into dimers and tetramers, ultimately creating a characteristic bead-like network distributed throughout the basement membranes and interstitial spaces of tissues such as skin, muscle, liver, and pancreas. The alpha-1 chain contains a glycine-rich collagenous domain essential for the triple-helical structure, along with non-collagenous domains that bind to extracellular components like laminin and fibronectin and to cell-surface receptors of the integrin family. Through these interactions, the protein anchors tissue integrity, cell adhesion, and signal transduction, functions so fundamental that mutations in COL6A1 cause inherited muscular connective tissue disorders such as Bethlem myopathy and Ullrich-type congenital muscular dystrophy.

What makes COL6A1 compelling in oncology is its pattern of abnormal overexpression across a striking range of malignancies. In pancreatic cancer, expression levels in tumor tissues exceed those of adjacent normal tissue by more than tenfold, and the excess is closely linked to distant metastasis and vascular invasion, standing out as an independent prognostic risk factor for survival. In osteosarcoma, the gene is markedly elevated, particularly at lung metastatic sites, where its overexpression appears to facilitate metastasis by inhibiting the STAT1 signaling pathway and activating cancer-associated fibroblasts in lung tissue. In sarcomas generally, high COL6A1 expression correlates positively with neutrophil infiltration and with significantly reduced overall and disease-specific survival. Silencing the gene in laboratory settings suppresses the migratory and invasive capabilities of pancreatic cancer cells and reverses epithelial-mesenchymal transition, the process by which tumor cells acquire the mobility needed to spread. Yet, as the review emphasizes, experimental verification of these mechanisms specifically within cholangiocarcinoma has been lacking.

The authors propose that in cholangiocarcinoma, COL6A1 is produced mainly by activated stromal cells rather than by the tumor cells themselves. Cancer-associated fibroblasts, the dominant stromal population, become highly activated under the influence of cytokines such as transforming growth factor-beta and interleukin-6 secreted by tumor cells, and hepatic stellate cells, a stromal cell type specific to the liver, can synthesize large amounts of collagen upon activation. Based on patterns observed in pancreatic cancer and osteosarcoma, the review hypothesizes that COL6A1 expression in cholangiocarcinoma tissue is considerably higher than in normal bile duct tissue, predominantly distributed in the tumor stroma, and positively correlated with the degree of fibrosis. The authors further speculate that expression may be highest in hilar cholangiocarcinoma, which exhibits sclerosing features with abundant fibroblasts, followed by intrahepatic disease with its pronounced stellate cell activation, and lowest in distal tumors with their relatively sparse stroma.

The mechanistic heart of the review lies in describing how COL6A1 could drive malignant progression through several synergistic pathways. First, the protein mediates matrix remodeling: secreted COL6A1 assembles into type VI collagen that interweaves with other matrix components to create a dense network, intensifying stromal fibrosis and increasing matrix stiffness. This stiffness transmits mechanical signals that induce cytoskeletal reorganization in tumor cells, enhancing their migration and their ability to break through tissue barriers. Evidence from pancreatic cancer suggests COL6A1 is closely associated with matrix metalloproteinase activity; knocking down the gene downregulates MMP2 and MMP9, inhibiting matrix degradation and tumor invasion. By analogy, COL6A1 in cholangiocarcinoma may locally degrade the extracellular architecture and disrupt basement membranes, clearing the way for invasion and metastasis.

Second, COL6A1 appears to regulate the activation and function of cancer-associated fibroblasts themselves, constructing what the authors describe as a positive feedback loop. The protein drives the phenotypic transformation of quiescent fibroblasts into activated cancer-associated fibroblasts, upregulating canonical markers such as alpha-smooth muscle actin and fibroblast-activated protein, expanding the pool of activated stromal cells, and reprogramming their secretory output toward oncogenic mediators including TGF-beta, CTGF, and SDF-1. These factors act on tumor cells in a paracrine fashion, aggravating malignant phenotypes while further exacerbating fibrosis. Third, through integrin binding, COL6A1 activates downstream signaling cascades, principally the PI3K/AKT and MAPK pathways, which promote cell cycle progression, inhibit apoptosis, induce epithelial-mesenchymal transition, and enhance invasive capacity. In osteosarcoma, COL6A1 additionally interacts with SOCS5 to promote the ubiquitination and degradation of STAT1, suppressing an antitumor signaling pathway and facilitating metastasis.

Perhaps most provocative is the proposed role of COL6A1 in shaping the tumor’s immune landscape. In sarcoma, the protein’s expression correlates significantly with neutrophil infiltration, and its co-expression with immune-related genes suggests a broader immunomodulatory function. The review outlines how COL6A1 may recruit and activate immunosuppressive cells, including myeloid-derived suppressor cells and regulatory T cells, which dampen antitumor immunity by depleting nutrients, producing inhibitory metabolites, and secreting anti-inflammatory cytokines such as IL-10 and TGF-beta. It may simultaneously inhibit the proliferation and cytotoxicity of effector T cells and natural killer cells, drive tumor-associated macrophages toward the pro-tumor M2 phenotype, and, through the dense fibrotic barrier it helps create, physically block functional immune cells from reaching the tumor parenchyma. This combination of immune suppression and physical exclusion could substantially weaken the efficacy of immunotherapy in cholangiocarcinoma.

The same fibrotic barrier may underlie treatment resistance more broadly. The review argues that COL6A1-driven matrix accumulation impedes the delivery of chemotherapeutic and targeted drugs, reducing their concentration within tumor tissue. Meanwhile, the CAF-TGF-beta axis can upregulate multidrug resistance genes such as MDR1, the COL6A1-activated PI3K/AKT pathway upregulates anti-apoptotic Bcl-2 family proteins that desensitize cells to drug-induced death, and hypoxia-driven HIF-1alpha signaling promotes metabolic reprogramming and resistance to both radiotherapy and chemotherapy. On the clinical side, the authors envision COL6A1 as a potential diagnostic and prognostic biomarker, detectable through immunohistochemistry, quantitative PCR, or blood-based assays, possibly in combination with established markers like CA19-9, and as a therapeutic target addressable through RNA interference, gene editing, blocking antibodies, or combination strategies with FGFR inhibitors and immunotherapies.

The authors are careful to stress the limits of the current evidence. Most of the regulatory pathways they describe have been extrapolated from other malignancies, direct research on COL6A1 in cholangiocarcinoma remains scarce, and no large-scale clinical cohorts have yet confirmed its diagnostic or prognostic value in this disease. Conventional monolayer cell models fail to recapitulate the highly fibrotic stromal microenvironment, and spatial information about COL6A1 localization and cell-to-cell crosstalk is still unavailable. To close these gaps, the review lays out a research agenda spanning multi-omics screening using TCGA and GEO datasets, single-cell RNA sequencing and spatial transcriptomics to pinpoint the cellular origin of stromal COL6A1, large clinical trials collecting tumor and serum samples, stroma-containing organoid models for drug screening, and investigation of the transcription factors and epigenetic modifications that drive the gene’s overexpression. If that agenda succeeds, a protein long viewed as mere structural scaffolding could emerge as a new biomarker and therapeutic target for one of medicine’s most lethal cancers.

Subject of Research: The role of the extracellular matrix protein COL6A1 in cholangiocarcinoma tumor stroma and tumor progression

Article Title: Expression of COL6A1 in Tumor Matrix of Cholangiocarcinoma and Its Mechanism of Tumor Progression

Article References: Zhang, W., Gao, C., Lan, C., Dong, J., Xu, B., Li, Y., Dai, J., Che, B., Li, C., Dong, G., Wu, Y., Li, B., Yang, C., & Kong, L. (2026). Expression of COL6A1 in Tumor Matrix of Cholangiocarcinoma and Its Mechanism of Tumor Progression. Cancer Reports, 9(10), Article e70716. https://doi.org/10.1002/cnr2.70716

Image Credits: AI Generated

DOI: 10.1002/cnr2.70716

Keywords: cholangiocarcinoma, COL6A1, type VI collagen, tumor microenvironment, extracellular matrix, cancer-associated fibroblasts, stromal fibrosis, immune evasion, drug resistance, biomarker, PI3K/AKT signaling, bile duct cancer

The regimen under investigation pairs trifluridine/tipiracil, an oral drug commonly abbreviated as FTD/TPI, with nanoliposomal irinotecan, a nanoparticle-encapsulated formulation of the classic chemotherapy agent irinotecan. Both components have already demonstrated clinical activity in gastrointestinal malignancies, but the logic of the combination goes deeper than convenience. Trifluridine is a thymidine analog that incorporates itself into replicating DNA and disrupts synthesis, while tipiracil inhibits the enzyme that would otherwise rapidly degrade trifluridine in the liver, thereby sustaining effective drug levels after oral administration. Nanoliposomal irinotecan, meanwhile, wraps the topoisomerase I inhibitor irinotecan inside a lipid bilayer roughly one hundred nanometers across, prolonging its circulation in the bloodstream and altering its distribution toward tumor tissue. The researchers hypothesize that these two mechanisms may produce synergistic antitumor effects when deployed together.

TRITICC-2 is structured as a prospective, open-label, multicenter, single-arm phase II trial conducted at academic centers across Germany. The single-arm design means that all enrolled patients receive the experimental combination, and results will be compared against historical benchmarks rather than a concurrent control group. This approach is common for early-phase studies in rare cancers, where the small patient population makes randomized designs difficult and slow. A total of 38 patients are planned for enrollment, all of whom must have histologically confirmed, unresectable or metastatic biliary tract cancer and documented disease progression on gemcitabine-based first-line therapy. Recruitment was initiated in late 2025 and is ongoing, with efficacy, safety, and translational analyses still pending.

The treatment schedule reflects a careful balancing of efficacy against toxicity. Patients receive oral trifluridine/tipiracil on days one through five of each cycle, combined with an intravenous infusion of nanoliposomal irinotecan on day one. Cycles repeat every fourteen days, and treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent. This two-week rhythm allows the oral component to hit the tumor repeatedly during each cycle while the long-circulating liposomal formulation maintains a sustained presence. The primary endpoint of the trial is progression-free survival, the length of time patients live without their disease advancing, which is a clinically meaningful measure in a setting where cure is not the realistic goal.

Secondary endpoints broaden the picture considerably. The investigators will track overall survival, the objective response rate as measured by standard imaging criteria, and the safety profile of the combination, graded according to the National Cancer Institute’s common toxicity criteria. Importantly, the trial also incorporates health-related quality of life assessments using validated instruments, including the EORTC QLQ-C30 questionnaire and the EQ-5D-5L. This attention to how patients actually feel and function during treatment matters enormously in a palliative setting, where a regimen that adds weeks of survival at the cost of debilitating side effects may offer little real benefit. The open-label design means patients and physicians know which treatment is being given, which is typical for trials of this size and phase but does introduce potential bias in subjective endpoints.

Beyond the clinical measurements, TRITICC-2 includes an optional translational research program that could prove scientifically valuable in its own right. Participants may undergo serial liquid biopsies, meaning repeated analyses of cell-free DNA and other biomarkers circulating in their blood, allowing researchers to track the molecular evolution of their tumors over time without repeated invasive tissue biopsies. By correlating these biomarker dynamics with treatment response and resistance, the investigators hope to identify markers associated with benefit from the combination. In an era when precision oncology increasingly depends on understanding which molecular features predict drug sensitivity, such prospective translational data from a rare cancer are genuinely scarce and correspondingly precious.

The trial’s governance structure follows the rigorous standards expected of modern European clinical research. The study is registered under the European Union Clinical Trials Regulation with the number EUCT 2024-517330-18-00, and its protocol is publicly accessible through the CTIS portal. Heinrich-Heine-University Düsseldorf serves as the sponsor, while the study is fully funded by Les Laboratoires Servier as an investigator-initiated trial, meaning the scientific questions and study design are driven by the academic investigators rather than the company. An independent data monitoring committee, composed of two gastroenterology specialists and one biostatistician, all of whom have declared no competing interests, reviews safety data twice a year and can request additional reviews at any time, with authority to recommend continuation, modification, or termination of the trial.

Quality assurance measures embedded in the protocol underscore the seriousness of the effort. A risk-based monitoring strategy ensures that every participating site receives at least one on-site visit per year, with visits concentrated on the data and processes most critical to study integrity. These on-site activities are complemented by centralized monitoring performed by data managers and biostatisticians. Written informed consent is required from all participants, and the trial operates under Good Clinical Practice standards and the German Medicine Act. Notably, no interim efficacy analyses are planned, which avoids the statistical complications of repeatedly testing the data, and the investigators have committed to publishing results regardless of whether the outcome is positive or negative, a pledge that remains disappointingly rare in clinical research.

For patients with advanced biliary tract cancer, the stakes of this trial could hardly be higher. The disease encompasses cholangiocarcinoma in its intrahepatic, perihilar, and distal forms as well as gallbladder carcinoma, and together these malignancies account for a substantial burden of cancer mortality worldwide, with incidence rising in many countries. Second-line treatment options after gemcitabine failure have historically delivered limited benefit, and while molecularly targeted therapies have emerged for the small subset of patients with actionable mutations such as IDH1 or FGFR2 alterations, the majority of patients still lack personalized options. A well-tolerated, orally anchored combination regimen could, if successful, offer a practical new standard that does not require specialized molecular testing infrastructure.

The TRITICC-2 study also illustrates a broader trend in oncology drug development: the intelligent repurposing of established agents into rational combinations for underserved tumor types. Neither trifluridine/tipiracil nor nanoliposomal irinotecan is a new molecule, but their pairing applies mechanistic reasoning and formulation science to a population with high unmet medical need. With enrollment underway and results still to come, the trial will not deliver answers immediately. Yet its design, transparency, and translational ambitions make it a study worth watching, both for the patients it may ultimately help and for the biomarker insights it may generate about how biliary tract cancers evolve and evade treatment.

Subject of Research: A phase II trial of trifluridine/tipiracil plus nanoliposomal irinotecan as second-line therapy for advanced biliary tract cancer

Article Title: Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2)

Article References: Kehmann, L., Götze, T., Gonzalez-Carmona, M., Foerster, F., Berres, M., Mohr, R., Koch, A., Das, S., Drusenheimer, N., Kebede, T., Joerdens, M., Luedde, T., & Roderburg, C. (2026). Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2). BMC Cancer. https://doi.org/10.1186/s12885-026-17089-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17089-6

Keywords: biliary tract cancer, cholangiocarcinoma, trifluridine/tipiracil, nanoliposomal irinotecan, phase II trial, second-line therapy, progression-free survival, liquid biopsy, clinical trial, oncology, chemotherapy, translational research